Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis

15 Nov 2023

Abstract excerpt

ABSTRACT Contezolid is a new oxazolidinone with in vitro and in vivo activity against Mycobacterium tuberculosis comparable to that of linezolid. Pre-clinical and clinical safety studies suggest it may be less toxic than linezolid, making contezolid a potential candidate to replace linezolid in the treatment of drug-resistant tuberculosis. We evaluated the dose-ranging activity of contezolid, alone and in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimicrobial Resistance in Staphylococcus
Share to Mycobacterium research and diagnosis
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37966090
DOI: 10.1128/aac.00789-23

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosisPMID 37966090Read ↗

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosisSemantic proximity Read ↗

In vitro activities of contezolid (MRX-I) against drug-sensitive and drug-resistant Mycobacterium tuberculosisSemantic proximity Read ↗

Drug Degradation Caused by mce3R Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In VitroSemantic proximity Read ↗

Drug degradation caused by <i>mce3R</i> mutations confers contezolid (MRX-I) resistance in <i>Mycobacterium tuberculosis</i>Semantic proximity Read ↗

Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in ChinaSemantic proximity Read ↗

Next-generation diarylquinolines improve sterilizing activity of regimens with pretomanid and the novel oxazolidinone TBI-223 in a mouse tuberculosis modelSemantic proximity Read ↗

Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practiceSemantic proximity Read ↗

Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice modelsSemantic proximity Read ↗

Multicentre evaluation of in vitro activity of contezolid against drug-resistant Staphylococcus and Enterococcus.Semantic proximity Read ↗

Contribution of telacebec to novel drug regimens in a murine tuberculosis modelSemantic proximity Read ↗

Comparative In Vitro Drug Susceptibility Study of Five Oxazolidinones Against Mycobacterium tuberculosis in Hainan, ChinaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.